<- Go Home
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Market Cap
$4.4M
Volume
215.7K
Cash and Equivalents
$3.3M
EBITDA
-$9.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$4.4M
Profit Margin
956.12%
52 Week High
$7.20
52 Week Low
$0.45
Dividend
N/A
Price / Book Value
-0.31
Price / Earnings
-0.09
Price / Tangible Book Value
-0.29
Enterprise Value
$9.0M
Enterprise Value / EBITDA
-0.95
Operating Income
-$9.5M
Return on Equity
127.46%
Return on Assets
-71.91
Cash and Short Term Investments
$5.0M
Debt
$156.7K
Equity
$6.0M
Revenue
$462.6K
Unlevered FCF
-$1.4M
Sector
Pharmaceuticals
Category
N/A